Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways
出版年份 2020 全文链接
标题
Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways
作者
关键词
Vinorelbine, Afatinib, NSCLC, EGFR, p53
出版物
BIOMEDICINE & PHARMACOTHERAPY
Volume 134, Issue -, Pages 111144
出版商
Elsevier BV
发表日期
2020-12-24
DOI
10.1016/j.biopha.2020.111144
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- JNK signaling in cancer cell survival
- (2019) Qinghua Wu et al. MEDICINAL RESEARCH REVIEWS
- Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway
- (2019) Xiaopei Tong et al. CHEMICAL & PHARMACEUTICAL BULLETIN
- Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer
- (2019) Zi-Yi Xu et al. OncoTargets and Therapy
- Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
- (2019) Daphné Morel et al. Nature Reviews Clinical Oncology
- Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
- (2018) D Westover et al. ANNALS OF ONCOLOGY
- Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2
- (2018) Rastislav Bahleda et al. BRITISH JOURNAL OF CANCER
- Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors
- (2018) Mahaveer Singh et al. DRUG DISCOVERY TODAY
- E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer
- (2018) Shuo Wang et al. FEBS LETTERS
- Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines
- (2018) Ines De Pauw et al. Molecular Oncology
- Insights of Crosstalk between p53 Protein and the MKK3/MKK6/p38 MAPK Signaling Pathway in Cancer
- (2018) Lorenzo Stramucci et al. Cancers
- Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry
- (2018) Xiaoyun Lu et al. MEDICINAL RESEARCH REVIEWS
- Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
- (2018) Gonzalo Recondo et al. Nature Reviews Clinical Oncology
- Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis
- (2018) A. Camerini et al. Clinical & Translational Oncology
- IL-17A/IL-17RA promotes invasion and activates MMP-2 and MMP-9 expression via p38 MAPK signaling pathway in non-small cell lung cancer
- (2018) Zhenhua Wu et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- The ERK and JNK pathways in the regulation of metabolic reprogramming
- (2018) Salvatore Papa et al. ONCOGENE
- Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy
- (2018) Meghan Leary et al. Cancers
- Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
- (2018) Tatsuya Nagano et al. Cells
- Chemosensitizing effect of Paris Saponin I on Camptothecin and 10-hydroxycamptothecin in lung cancer cells via p38 MAPK, ERK, and Akt signaling pathways
- (2017) Zhen Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer
- (2017) C Hardin et al. EXPERT OPINION ON PHARMACOTHERAPY
- Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer
- (2017) Jaafar Bennouna Future Oncology
- P38 pathway as a key downstream signal of connective tissue growth factor to regulate metastatic potential in non-small-cell lung cancer
- (2016) Shinichiro Kato et al. CANCER SCIENCE
- Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress
- (2016) Jaafar Bennouna et al. Future Oncology
- Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
- (2016) Nadia Harbeck et al. LANCET ONCOLOGY
- Oral vinorelbine: a feasible and safe partner for radiotherapy in the treatment of locally advanced non-small cell lung cancer
- (2016) Francesco Perri et al. OncoTargets and Therapy
- Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer
- (2015) Hirofumi Mukai et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
- (2015) Javier Cortés et al. LANCET ONCOLOGY
- PI3K/Akt-mediated regulation of p53 in cancer
- (2014) Aswin G. Abraham et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Targeting RAS–ERK signalling in cancer: promises and challenges
- (2014) Ahmed A. Samatar et al. NATURE REVIEWS DRUG DISCOVERY
- Afatinib—new therapy option for EGFR-mutant lung cancer
- (2013) Helena A. Yu et al. Nature Reviews Clinical Oncology
- p38 mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients
- (2012) David Planchard et al. CANCER
- Inhibition of p38 MAPK-Dependent Excision Repair Cross-Complementing 1 Expression Decreases the DNA Repair Capacity to Sensitize Lung Cancer Cells to Etoposide
- (2011) M.-S. Tsai et al. MOLECULAR CANCER THERAPEUTICS
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transcriptional down-regulation of Bcl-2 by vinorelbine: Identification of a novel binding site of p53 on Bcl-2 promoter
- (2009) Véronique Bourgarel-Rey et al. BIOCHEMICAL PHARMACOLOGY
- The genetics of the p53 pathway, apoptosis and cancer therapy
- (2008) Alexei Vazquez et al. NATURE REVIEWS DRUG DISCOVERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started